Researchers at the University of Michigan found that 80 percent of participants with suspected dementia had not been told they had the disease or showed early signs.
The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...